INVESTUDY.ORG
  • Home
  • ECONOMY
  • STOCK INVESTMENT
  • COMPANY ANALYSIS
  • CRYPTOCURRENCY
  • TAXES/LAWS
  • EDUCATION
  • REAL ESTATE
No Result
View All Result
SUBSCRIBE
INVESTUDY.ORG
  • Home
  • ECONOMY
  • STOCK INVESTMENT
  • COMPANY ANALYSIS
  • CRYPTOCURRENCY
  • TAXES/LAWS
  • EDUCATION
  • REAL ESTATE
No Result
View All Result
Investudy.org
No Result
View All Result
Home BUSINESS

These Two Stocks Have Quadrupled Their Dividends Over the Past Decade

2025-04-25
in BUSINESS, STOCK INVESTMENT
These Two Stocks Have Quadrupled Their Dividends Over the Past Decade
74
SHARES
1.2k
VIEWS
Share on FacebookShare on Twitter

You might also like

Essential Economic Indicators You Must Watch to Understand Global Markets

How to Identify Market Tops and Bottoms in the Stock Market

Read the 10-K and 10-Q Reports! A Guide to Essential SEC Filings for Investors

Stock selection is everything in investing. While thousands of publicly traded companies exist, not all of them are worth investing your hard-earned money in.

One of the more objective measures of investment quality is a strong track record of dividend growth. This is because sustained dividend increases are only possible with the corresponding earnings growth to support them. Below are two healthcare sector dividend payers that have achieved remarkable dividend growth over the past decade.


Amgen: A Diversified Pharmaceutical Business

Generating $26.3 billion in revenue in 2022, Amgen (NASDAQ: AMGN) is one of the world’s largest pharmaceutical companies. As expected from such a massive California-based drug company, Amgen has a well-balanced revenue stream.

The company boasts a portfolio of nine blockbuster drugs, led by its immunotherapy drug Enbrel, which generated $4.1 billion in revenue in 2022. Thanks to this impressive product lineup, Amgen has managed to significantly increase its dividend over the past decade. Its quarterly dividend has grown more than fourfold, from $0.47 per share in 2013 to $2.13 per share today.

There are plenty of reasons to believe that Amgen’s management can continue its rapid dividend growth.

  • First, Amgen recently launched Amjevita, a biosimilar to AbbVie’s blockbuster drug Humira, which could generate nearly $1 billion in annual revenue.
  • Second, new drugs such as Lumakras (a lung cancer treatment) and Tezspire (an asthma treatment co-developed with AstraZeneca) could also become blockbusters.
  • Additionally, Amgen has dozens of other compounds in various stages of clinical trials. These factors explain why analysts believe Amgen’s earnings will grow at a mid-single-digit annual rate over the next five years—a projection that may actually be conservative.

Finally, Amgen’s dividend payout ratio is expected to be 48% in 2023, leaving ample cash for acquisitions, debt repayment, and share buybacks. It would be surprising if Amgen does not deliver high single-digit annual dividend increases in the mid-term. The stock already offers a 3.5% dividend yield, more than double the S&P 500’s 1.6% yield.

Moreover, Amgen trades at a forward price-to-earnings (P/E) ratio of 12.9, which is slightly cheaper than the pharmaceutical industry’s average forward P/E of 13.6. Simply put, Amgen remains an attractive choice for long-term dividend growth investors.


LeMaitre Vascular: Specialization Pays Off

Berkshire Hathaway CEO Warren Buffett is well-known for his concept of the “circle of competence.” The idea is simple: know what you’re good at and stick to it. While Buffett often applies this principle to investing, it’s equally critical for company management to achieve success while minimizing failures.

Few companies exemplify this principle better than LeMaitre Vascular (NASDAQ: LMAT). LeMaitre focuses exclusively on the peripheral vascular disease medical device market, and its specialization has paid off. The company holds the No. 1 or No. 2 market share in nine out of twelve product categories, including vascular grafts, carotid shunts, and occlusion catheters.

Thanks to its niche market leadership, LeMaitre’s management has increased its quarterly dividend per share from $0.03 in 2013 to $0.14 today. This rapid dividend growth more than compensates for its low starting yield of 1.1%.

Looking ahead, LeMaitre’s products will likely see strong demand due to rising global physical inactivity rates. Combined with acquisitions and new product launches, this should drive solid revenue growth in the coming years. Additionally, with a projected payout ratio of approximately 48% in 2023, the company is well-positioned to continue impressive dividend growth.

Most importantly, LeMaitre looks attractively priced at its current stock price of $51. Its Shiller P/E ratio of 59.9 is significantly lower than its 10-year average of 91.2. The Shiller P/E ratio adjusts a company’s earnings for inflation over the past decade, providing a more accurate valuation measure.

This valuation helps explain why analysts have set an average 12-month target price of $58 per share, which is 13% higher than the current price.

Recommended For You

Essential Economic Indicators You Must Watch to Understand Global Markets

by investudy
2025-05-07
0

Across the world, both public institutions and private companies release a wide range of economic indicators that reflect the economic health of different countries. Fortunately, websites like TradingEconomics...

Read moreDetails

How to Identify Market Tops and Bottoms in the Stock Market

by investudy
2025-05-07
0
How to Identify Market Tops and Bottoms in the Stock Market

Many online trading platforms provided by securities firms offer a wide range of useful tools, charts, and indicators. Among them, the one I use most frequently is Webull,...

Read moreDetails

Read the 10-K and 10-Q Reports! A Guide to Essential SEC Filings for Investors

by investudy
2025-04-30
0
Read the 10-K and 10-Q Reports! A Guide to Essential SEC Filings for Investors

The 10-K and 10-Q reports are official documents that publicly traded companies are required to file with the U.S. Securities and Exchange Commission (SEC) under U.S. securities laws....

Read moreDetails

How to Calculate Fair Value of a Stock (Intrinsic Value Explained)

by investudy
2025-04-30
0

Fair value is considered the most reasonable price for a stock. It reflects the price or price range at which an asset or liability could be bought or...

Read moreDetails

What Defines a Company That Can Withstand Rising Interest Rates?

by investudy
2025-04-25
0
What Defines a Company That Can Withstand Rising Interest Rates?

In a rising interest rate environment, borrowing costs increase while consumer spending often slows down. So, what defines a company that can withstand these higher costs? Let’s explore...

Read moreDetails
Next Post

High-Yield Dividend Stocks to Buy During a Market Sell-Off

Please login to join discussion

Related News

Starbucks (SBUX) Stock Analysis (As of December 24, 2024)

Starbucks (SBUX) Stock Analysis (As of December 24, 2024)

2025-04-25
The Sahm Rule: A Key U.S. Recession Indicator

The Sahm Rule: A Key U.S. Recession Indicator

2025-04-29
3 High-Yield Dividend Stocks That Generate More Passive Income Than a 10-Year Treasury

3 High-Yield Dividend Stocks That Generate More Passive Income Than a 10-Year Treasury

2025-04-25

Browse by Category

  • BONDS
  • BUSINESS
  • COMPANY ANALYSIS
  • CRYPTOCURRENCY
  • ECONOMY
  • EDUCATION
  • REAL ESTATE
  • STOCK INVESTMENT
  • TAXES/LAWS

INVESTUDY.ORG

Learn about the basics of successful investing, the right investment attitude, and how to gain valuable insights for many investors to embark on the path to successful investing.

CATEGORIES

  • BONDS
  • BUSINESS
  • COMPANY ANALYSIS
  • CRYPTOCURRENCY
  • ECONOMY
  • EDUCATION
  • REAL ESTATE
  • STOCK INVESTMENT
  • TAXES/LAWS

BROWSE BY TAG

ai AI Boom Big Tech Stocks Bitcoin BOJ Rate Hike BPS Buffett Cryptocurrencies Currency Trading dividend Economy emotional intelligence relationships equity research etf fair value calculation Fed Tapering fundamental analysis Global Markets how to build meaningful connections intrinsic value Investment Strategies Japanese Interest Rates loneliness vs solitude Market Fear Market Signals NVIDIA Obligation S&P 500 Stimulus Trigger stock investing tips stock market timing stock valuation Strategy technical analysis toxic relationships signs U.S. Stock Market Unemployment Rate US Crypto Regulation value investing Visa Warren Buffett investing when to cut off someone Yen Carry Trade Yen Carry Trade Unwinding 배당주

© 2023 Investudy.org - Stock, cryptocurrency, economic news, and real estate information sharing.

No Result
View All Result
  • Home
  • ECONOMY
  • STOCK INVESTMENT
  • COMPANY ANALYSIS
  • CRYPTOCURRENCY
  • TAXES/LAWS
  • EDUCATION
  • REAL ESTATE

© 2023 Investudy.org - Stock, cryptocurrency, economic news, and real estate information sharing.

Are you sure want to unlock this post?
Unlock left : 0
Are you sure want to cancel subscription?